ATG 041
Alternative Names: ATG-041Latest Information Update: 16 Jun 2022
Price :
$50 *
At a glance
- Originator Antengene Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase modulators; Proto-oncogene protein c-mer modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 16 Jun 2022 ATG 041 is available for licensing as of 16 Jun 2022. https://www.antengene.com/partnerships
- 18 Nov 2021 Antengene Corporation announces intention to file IND application for ATG 041 in 2023
- 18 Nov 2021 Preclinical trials in Haematological malignancies in China (unspecified route) (Antengene Corporation pipeline, November 2021)